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Maintaining Safety with SARS-CoV-2 Vaccines
To the Editor: In the review article by Castells 
and Phillips on vaccines for the prevention of in-
fection with SARS-CoV-2 (published on Dec. 30 
at NEJM.org),1 the authors describe cases of ana-
phylaxis associated with the Pfizer–BioNTech 
messenger RNA (mRNA) vaccine. The estimated 
incidence of anaphylaxis is 1 in 100,000 injec-
tions, as compared with an expected incidence of 
1 in 1 million injections.2
The incidence of anaphylaxis after vaccina-
tion with the quadrivalent human papillomavirus 
(HPV) vaccine (Gardasil) has been estimated at 
1 in 190,000 injections3; this incidence is similar 
to that reported for the Pfizer–BioNTech vaccine. 
Polysorbate 80 is an excipient in Gardasil, and 
we identified polysorbate 80 as the culprit in a 
case of anaphylaxis that occurred in a young girl 
after the third intramuscular administration of 
that vaccine.4
Castells and Phillips note that the implica-
tions for the future use of SARS-CoV-2 vaccines, 
which are commonly formulated with polysor-
bate 80 (with a structure similar to that of poly-
ethylene glycol [PEG]), are unknown. Allergists 
should be aware that cross-reactive immediate 
hypersensitivity to macrogols (PEGs) and poly-
sorbates can occur. We have reported5 a case of 
multiple drug reaction due to hypersensitivity to 
PEGs of a wide variety of molecular weights, 
from PEG 80 to macrogol 6000.
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The authors reply: Rolla et al. cite a retrospec-
tive cohort study of 380,000 doses of HPV vac-
cine.1 That study included one case in which the 
timing of symptom onset (15 to 20 minutes) was 
consistent with anaphylaxis. The article by Badiu 
et al.2 provided evidence of potential reactivity to 
polysorbate 80 that is present in both the influ-
enza vaccine (Fluarix) and the HPV vaccine. How-
ever, the person with the reaction described by 
Kang et al.1 had a positive skin test with the HPV 
vaccine but a negative test with polysorbate 80 
and was never rechallenged. In a prospective study 
of 600,558 HPV vaccine doses administered, only 
one reported case of anaphylaxis was noted.3
Whether the PEG 2000 component of mRNA 
SARS-CoV-2 vaccines is implicated in anaphy-
laxis and other immediate reactions has not 
been established. Polysorbates are excipients in 
several SARS-CoV-2 vaccines that are under de-
velopment as well as in at least 20 vaccines li-
censed in the United States, where anaphylaxis 
has not been a prevalent signal.4
Allergy assessment that involves skin testing 
and challenges to PEG and derivatives including 
polysorbates is warranted. Research is under way 
to help define the population at risk and the 
mechanism or mechanisms of anaphylactic re-
actions to SARS-CoV-2 mRNA vaccines, as well 
as safe vaccine and medication use in this popu-
lation.4
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